This particular drug is released from its complex into the bloodstream, and the amphotericin B that remains in plasma is more than 90% bound to proteins, largely b-lipoprotein.  Approximately 2 to 5% of each dose appears in the urine when patients are on daily therapy.  Elimination of the drug appears to be unchanged.  Hepatic or biliary disease has no known effect on metabolism of the drug in human beings.  Because of the colossal size of amphotericin B, the human body has no good idea of what to do with the compound and for that reason the parent compound is hardly metabolized into more polar forms.